<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189055</url>
  </required_header>
  <id_info>
    <org_study_id>FBH-001</org_study_id>
    <nct_id>NCT04189055</nct_id>
  </id_info>
  <brief_title>Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.</brief_title>
  <acronym>CETIDYL</acronym>
  <official_title>Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. A Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS IHFB Cognacq-Jay</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS IHFB Cognacq-Jay</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan&#xD;
      in patients with neo wild-type colorectal cancer who have been previously treated for&#xD;
      metastatic disease.&#xD;
&#xD;
      Patients will be included in cohort #1 or cohort #2. The inclusion in cohort #2 will start&#xD;
      when the results of the cohort #1 are available.&#xD;
&#xD;
      Patient will receive either cetuximab alone (cohort #1) or cetuximab with irinotecan (cohort&#xD;
      #2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background - Rationale&#xD;
&#xD;
      KRAS and NRAS mutations are present in roughly 50% of patients with advanced colorectal&#xD;
      cancer and predict failure of anti-EGFR mabs therapies, thus genotyping colorectal cancer&#xD;
      (CRC) is mandatory for personalized treatments.&#xD;
&#xD;
      Research has been selectively concentrated on the emergence of resistant clones in the blood&#xD;
      of patients with wild-type (WT) RAS CRC as biomarker of anti-EGFR therapy resistance.&#xD;
&#xD;
      It has been suggested that patients with metastatic CRC harboring mutated primary tumors,&#xD;
      thus not candidate to EGFR inhibitors, frequently have WT RAS circulating tumor cells in&#xD;
      blood. Preliminary data suggest that patients with mutant KRAS colon cancer can frequently&#xD;
      (50%) switch to a prevalent WT KRAS disease in course of treatment with anti-angiogenic&#xD;
      drugs.&#xD;
&#xD;
      In patients with RAS wild-type colorectal cancer who previously received standard therapies,&#xD;
      anti-EGFR mabs achieve a response rate of 20% as monotherapy and 30-40% in combination with&#xD;
      irinotecan.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy of cetuximab in patients with pretreated&#xD;
      neo wild-type colorectal cancer using liquid biopsies for RAS molecular assessment&#xD;
&#xD;
      Study Objectives&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      • To evaluate the response rate using RECIST 1.1&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To evaluate progression-free survival (PFS), overall survival (OS)&#xD;
&#xD;
        -  To evaluate disease control rate (DCR)&#xD;
&#xD;
        -  To evaluate safety&#xD;
&#xD;
      Exploratory:&#xD;
&#xD;
        -  Frequency of neo wild-type tumors&#xD;
&#xD;
        -  Frequency of RAS and BRAF neomutations during treatment&#xD;
&#xD;
      Study Design Prospective multicentric single-arm open-label phase II study in to 2 successive&#xD;
      patient cohorts (cohort #1 followed by cohort #2).&#xD;
&#xD;
      Molecular screening using Idylla™ (Biocartis) ctKRAS and ctNRAS/BRAF Mutation Assays.&#xD;
&#xD;
      Cohort #1: Patients will be treated with cetuximab monotherapy (cetuximab 500mg/m² IV, day&#xD;
      1).&#xD;
&#xD;
      Cohort #2: Patients will be treated with cetuximab and irinotecan (cetuximab 500mg/m² IV, day&#xD;
      1; irinotecan 180mg/m² IV, day 1).&#xD;
&#xD;
      In both cohorts, treatment will be given intravenously every 14 days (q2w) until disease&#xD;
      progression or limiting toxicity. Tumor evaluations will be done with CT-scan (or MRI) every&#xD;
      8 weeks using RECIST v1.1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>4 months</time_frame>
    <description>Tumor measurements will be obtained at baseline and every 8 weeks following treatment initiation. At the investigator's discretion, tumor assessments may be repeated at any time if progressive disease is suspected. Tumor response and progression will be assessed by the Investigator using RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time interval from inclusion to the date of death from any cause. Assessed up to 12 months after the beginning of the study</time_frame>
    <description>OS is defined as the time interval from the date of inclusion to the date of death from any cause. Alive patients will be censored at the last date known to be alive, either during study treatment period or during follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>the time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 12 months after the beginning of the study</time_frame>
    <description>PFS is defined as the time interval from the date of inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Alive patients without progression will be censored at the last tumor assessment, either during study treatment period or during follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control rate</measure>
    <time_frame>from baseline until end of treatment, assessed up to 12 months after the beginning of the study</time_frame>
    <description>Disease control rate (DCR) is defined as the percentage of patients achieving CR, PR, or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Assessed from study entry to 1 month after last study drug administration, assessed up to 12 months after the beginning of the study</time_frame>
    <description>Frequency of adverse events using NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor biomarkers</measure>
    <time_frame>Assessed from study entry to end of study treatment, assessed up to 12 months after the beginning of the study</time_frame>
    <description>Tumor biomarkers will be tested : mismatch repair system (pMMR vs dMMR), HER1 (EGFR expression), HER2 expression, amphiregulin (AREG) and HER1 (EGFR GCN, cut-off 4.0), HER2, PI3KCA, PTEN, IRS2,</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Cancer Colorectal</condition>
  <arm_group>
    <arm_group_label>Cohort #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab monotherapy (500mg/m² IV, day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 500mg/m² IV, day 1</description>
    <arm_group_label>Cohort #1</arm_group_label>
    <arm_group_label>Cohort #2</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 180mg/m² IV, day 1</description>
    <arm_group_label>Cohort #2</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent and stated willingness to comply with&#xD;
             all study procedures and availability for the duration of the study,&#xD;
&#xD;
          2. Male or female subjects, ≥18 years of age,&#xD;
&#xD;
          3. ECOG performance status (ECOG PS, Appendix 15.1) ≤2,&#xD;
&#xD;
          4. Unresectable metastatic RAS mutant (either KRAS or NRAS tumor gene mutation)&#xD;
             colorectal cancer,&#xD;
&#xD;
          5. At least one (≥1) measurable and/or evaluable liver metastasis,&#xD;
&#xD;
          6. Prior therapy (resistant or intolerant) with fluoropyrimidines, oxaliplatin,&#xD;
             irinotecan and antiangiogenic agent (ie, bevacizumab and/or aflibercept),&#xD;
&#xD;
          7. Adequate hematologic and end-organ function, defined by the following laboratory test&#xD;
             results, obtained within 14 days prior to initiation of study treatment:&#xD;
&#xD;
             Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin&#xD;
             ≥9g/dL Adequate renal function: serum creatinine clearance (MDRD) ≥ 50 mL/min/1,73 m2&#xD;
             Adequate liver function: serum bilirubin ≤1.5x upper normal limit (ULN), alkaline&#xD;
             phosphatase &lt;5xULN, AST and ALT ≤5xULN, Adequate serum electrolyte levels (magnesium,&#xD;
             potassium, calcium) prior to initiation of study treatment,&#xD;
&#xD;
          8. Negative pregnancy test within 7 days prior to initiation of the study drug for female&#xD;
             patients of childbearing potential,&#xD;
&#xD;
          9. Effective contraception for both male and female subjects if the risk of conception&#xD;
             exists&#xD;
&#xD;
         10. Registration in a national health care system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or hypersensitivity reactions to any study drug,&#xD;
&#xD;
          2. Women who are pregnant or breastfeeding,&#xD;
&#xD;
          3. Inability to comply with study and follow-up procedures as judged by the Investigator,&#xD;
&#xD;
          4. Patient with BRAF mutant colorectal cancer&#xD;
&#xD;
          5. History of interstitial lung disease&#xD;
&#xD;
          6. Treatment with strong CYP3A4-enzyme inducers such as anticonvulsants (phenytoin,&#xD;
             phenobarbital or carbamazepine), rifampin, rifabutin and St. John's wort for patients&#xD;
             of cohort #2&#xD;
&#xD;
          7. Treatment with strong CYP3A4-enzyme inhibitors (e.g. grapefruit juice, clarithromycin,&#xD;
             indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir,&#xD;
             telaprevir, voriconazole) for patients of cohort #2&#xD;
&#xD;
          8. Treatment with strong UGT1A inhibitors (e.g. atazanavir, gemfibrozil, indinavir) for&#xD;
             patients of cohort # 2&#xD;
&#xD;
          9. Patients of cohort #2 with known UGT1A deficiency&#xD;
&#xD;
         10. Uncontrolled illness, including but not limited to ongoing bacterial, viral or fungal&#xD;
             infection requiring systemic therapy, metabolic dysfunction, physical examination/&#xD;
             clinical laboratory finding that leads to a reasonable suspicion of a&#xD;
             disease/condition that contraindicates the use of any of investigational drugs that&#xD;
             may affect the interpretation of the results, or that may render the subject at high&#xD;
             risk of treatment complications.&#xD;
&#xD;
         11. Patient with current intestinal obstruction or history of chronic inflammatory bowel&#xD;
             disease&#xD;
&#xD;
         12. Subjects under guardianship, curatorship or judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoist CHIBAUDEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franco-British Hospital - GCS IHFB Cognacq-Jay</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoist CHIBAUDEL, MD</last_name>
    <phone>0147595965</phone>
    <phone_ext>33</phone_ext>
    <email>benoist.chibaudel@ihfb.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Franco-British Hospital - GCS IHFB Cognacq-Jay</name>
      <address>
        <city>Levallois-Perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.</citation>
    <PMID>18316791</PMID>
  </reference>
  <reference>
    <citation>André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A; GERCOR. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013 Feb;24(2):412-419. doi: 10.1093/annonc/mds465. Epub 2012 Oct 5.</citation>
    <PMID>23041588</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):337-45.</citation>
    <PMID>15269313</PMID>
  </reference>
  <reference>
    <citation>Élez E, Kocáková I, Höhler T, Martens UM, Bokemeyer C, Van Cutsem E, Melichar B, Smakal M, Csőszi T, Topuzov E, Orlova R, Tjulandin S, Rivera F, Straub J, Bruns R, Quaratino S, Tabernero J. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-140. doi: 10.1093/annonc/mdu474. Epub 2014 Oct 15.</citation>
    <PMID>25319061</PMID>
  </reference>
  <reference>
    <citation>Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep 1;110(5):980-8.</citation>
    <PMID>17671985</PMID>
  </reference>
  <reference>
    <citation>Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 Nov 15;357(20):2040-8.</citation>
    <PMID>18003960</PMID>
  </reference>
  <reference>
    <citation>Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.</citation>
    <PMID>18946061</PMID>
  </reference>
  <reference>
    <citation>Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol. 2008 Jun;19(6):1141-5. doi: 10.1093/annonc/mdn020. Epub 2008 Feb 14.</citation>
    <PMID>18281264</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver metastasis</keyword>
  <keyword>KRAS</keyword>
  <keyword>NRAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

